Lucinda Ross, APRN
Adult Health · Salt Lake City, UTNPI 1831340389
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,309 and has fallen 61.8% since, to $501 in 2025. Among adult health clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$925
- Lilly USA, LLC$550
- Novo Nordisk$516
- Tandem Diabetes Care, Inc.$377
- Dexcom, Inc.$255
- Amgen$219
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,32496%
- Education$1664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 73 | $925 |
| Lilly USA, LLC | 41 | $550 |
| Novo Nordisk | 57 | $516 |
| Tandem Diabetes Care, Inc. | 10 | $377 |
| Dexcom, Inc. | 13 | $255 |
| Amgen(2 entities) | 9 | $219 |
| BETA Bionics, Inc. | 13 | $212 |
| Novartis | 7 | $172 |
| Boehringer Ingelheim | 7 | $125 |
| AstraZeneca(2 entities) | 6 | $102 |
| Radius Health, Inc. | 6 | $102 |
| Xeris Pharmaceuticals, Inc. | 5 | $99 |
| Amryt Pharma Holdings Ltd | 4 | $71 |
| Insulet Corporation | 3 | $71 |
| Recordati_rare_diseases_inc. | 3 | $70 |
| Exeltis, USA Inc. | 1 | $67 |
| Alfasigma USA, Inc. | 3 | $63 |
| Chiesi USA, Inc. | 3 | $61 |
| Bayer | 4 | $57 |
| Corcept Therapeutics | 3 | $51 |
| Medtronic | 2 | $45 |
| Sequel Med Tech, LLC | 1 | $38 |
| AbbVie | 2 | $34 |
| GRT US Holding, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Cequr Corporation | 1 | $20 |
| Pfizer | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,491 in reported general payments places this provider in the 95th percentile of 53 adult health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 181 | $251,413 |
| OzempicSemaglutide | 78 | $102,110 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $73,276 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $66,117 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $59,389 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $54,534 |
| TrulicityDulaglutide | 42 | $52,805 |
| JardianceEmpagliflozin | 60 | $50,123 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $34,549 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $27,597 |
| TradjentaLinagliptin | 26 | $27,212 |
| Novolog FlexpenInsulin Aspart | 87 | $26,884 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $24,385 |
| NovologInsulin Aspart | 74 | $24,191 |
| Humalog Kwikpen U-100Insulin Lispro | 49 | $21,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $550 | $318,197275 claims |
| Novo NordiskOzempic, Novolog, Tresiba | $516 | $141,679165 claims |
| Boehringer IngelheimJardiance, Tradjenta | $125 | $77,33686 claims |
| Sanofi-aventis U.S. LLCLantus | $26 | $4,26117 claims |
| AbbVieSynthroid | $34 | $1,82036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 adult health providers in Utah.
Other adult health in Salt Lake City
- Kristin LarsonSalt Lake City$75K
- Joanne NamSalt Lake City$3K
- Irene CheongSalt Lake City$2K
- Rachel StraightSalt Lake City$1K
- Marimar Otero-RojasSalt Lake City$891
- Elizabeth CardenasSalt Lake City$851
- Bennett NavarroSalt Lake City$656
- Laura CannonSalt Lake City$464
- Karen FronkSalt Lake City$396
- Cristine TuttleSalt Lake City$333
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.